Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 733
- Registration Number
- NCT06097364
- Locations
- 🇨🇱
Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Bridge TherapyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Multigated Acquisition ScanBiological: T-cell Receptor-engineered T-cellsProcedure: X-Ray Imaging
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06094842
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06092047
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC (AnHui Provincial Hospital), Hefei, Anhui, China
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06093841
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06096038
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 904
- Registration Number
- NCT06091865
- Locations
- 🇫🇷
Hopital Saint Vincent-de-Paul, Lille, Nord, France
🇰🇷St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yeouido St. Marys Hospital, Seoul, Korea, Republic of
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT06085742
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT06083922
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06083844
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.